ASH19: AZ’s Calquence throws gauntlet down to ImbruvicaAstraZeneca’s resurgent cancer division could have another winner on its hands. Stellar data with newly-approved BTK inhibitor Calquence Share XASH19: AZ’s Calquence throws gauntlet down to Imbruvicahttps://pharmaphorum.com/news/ash19-azs-calquence-throws-gauntlet-down-to-imbruvica/
NICE backs Lynparza across the board for BRCA+ovarian cancerAstraZeneca and MSD’s Lynparza has become the first PARP inhibitor to be recommended for all lines of maintenance Share XNICE backs Lynparza across the board for BRCA+ovarian cancerhttps://pharmaphorum.com/news/nice-backs-lynparza-across-the-board-for-brca-ovarian-cancer/
FDA grants AZ’s Imfinzi fast review in new lung cancer useThe FDA has granted AstraZeneca’s Imfinzi immunotherapy a faster six-month review in patients with extensive-stage small cell lung Share XFDA grants AZ’s Imfinzi fast review in new lung cancer usehttps://pharmaphorum.com/news/fda-grants-azs-imfinzi-fast-review-in-new-lung-cancer-use/
AZ and Novoheart collaborate on ‘heart in a jar’, to develop new HF drugsStem cell biotech Novoheart is to collaborate with AstraZeneca to develop a “heart in a jar” that will Share XAZ and Novoheart collaborate on ‘heart in a jar’, to develop new HF drugshttps://pharmaphorum.com/news/az-and-novoheart-collaborate-on-heart-in-a-jar-to-d/
FDA nod for AZ’s Calquence sets up new Imbruvica showdownAbbVie and Johnson & Johnson are facing a challenge to their blockbuster chronic lymphocytic leukaemia drug Imbruvica from Share XFDA nod for AZ’s Calquence sets up new Imbruvica showdownhttps://pharmaphorum.com/news/fda-nod-for-azs-calquence-sets-up-new-imbruvica-showdown/
AstraZeneca, Merck cue up FDA verdict on selumetinib next yearAfter failing to make the grade in multiple cancer types, AstraZeneca and Merck & Co/MSD’s selumetinib could get Share XAstraZeneca, Merck cue up FDA verdict on selumetinib next yearhttps://pharmaphorum.com/news/astrazeneca-merck-cue-up-fda-verdict-on-selumetinib-next-year/
AZ fleshes out positive trial of revitalised lupus drug anifrolumabAfter being all-but written off a year ago, AstraZeneca’s anifrolumab has been reborn with new data that suggest Share XAZ fleshes out positive trial of revitalised lupus drug anifrolumabhttps://pharmaphorum.com/news/az-fleshes-out-positive-trial-of-revitalised-lupus-drug-anifrolumab/
AZ preps for US filing of kidney disease anaemia drugAstraZeneca is gearing up for a US filing for its roxadustat, a potential drug for patients with anaemia Share XAZ preps for US filing of kidney disease anaemia drughttps://pharmaphorum.com/news/az-preps-for-us-filing-of-kidney-disease-anaemia-drugs/
AZ’s trio of new China R&D initiatives includes $1bn fundAstraZeneca has announced three research initiatives in China including a potential $1 billion investment fund, in a country Share XAZ’s trio of new China R&D initiatives includes $1bn fundhttps://pharmaphorum.com/news/az-announces-trio-rd-initiatives-in-china-including-1bn-investment-fund/
